243 related articles for article (PubMed ID: 29349693)
21. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
22. Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in Patients With Inflammatory Bowel Diseases.
Marzano AV; Tavecchio S; Berti E; Gelmetti C; Cugno M
Medicine (Baltimore); 2015 Nov; 94(45):e1818. PubMed ID: 26559252
[TBL] [Abstract][Full Text] [Related]
23. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
24. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
25. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics.
Stoffel E; Maier H; Riedl E; Brüggen MC; Reininger B; Schaschinger M; Bangert C; Guenova E; Stingl G; Brunner PM
Br J Dermatol; 2018 May; 178(5):1151-1162. PubMed ID: 29143979
[TBL] [Abstract][Full Text] [Related]
26. Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease.
Gholam-Mostafaei FS; Yadegar A; Aghdaei HA; Azimirad M; Daryani NE; Zali MR
Curr Res Transl Med; 2020 Aug; 68(3):125-130. PubMed ID: 32414632
[TBL] [Abstract][Full Text] [Related]
27. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
Xie W; Xiao S; Huang H; Zhang Z
Front Immunol; 2022; 13():847160. PubMed ID: 35300336
[TBL] [Abstract][Full Text] [Related]
28. Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?
Decock A; Van Assche G; Vermeire S; Wuyts W; Ferrante M
J Crohns Colitis; 2017 Mar; 11(3):378-383. PubMed ID: 27591675
[TBL] [Abstract][Full Text] [Related]
29. Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors.
Eickstaedt J; Paller AS; Lund E; Murphrey M; Brandling-Bennett H; Maurano M; Fernandez Faith E; Holland KE; Ibler E; Liang MG; Todd PS; Siegfried E; Igelman S; Cordoro KM; Tollefson MM
JAMA Dermatol; 2023 Jun; 159(6):637-642. PubMed ID: 37043214
[TBL] [Abstract][Full Text] [Related]
30. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
[TBL] [Abstract][Full Text] [Related]
31. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
Colman RJ; Rubin DT
J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
[TBL] [Abstract][Full Text] [Related]
32. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.
Cheon JH
J Gastroenterol Hepatol; 2017 Apr; 32(4):769-777. PubMed ID: 27723166
[TBL] [Abstract][Full Text] [Related]
33. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
Guerra I; Pérez-Jeldres T; Iborra M; Algaba A; Monfort D; Calvet X; Chaparro M; Mañosa M; Hinojosa E; Minguez M; Ortiz de Zarate J; Márquez L; Prieto V; García-Sánchez V; Guardiola J; Rodriguez GE; Martín-Arranz MD; García-Tercero I; Sicilia B; Masedo Á; Lorente R; Rivero M; Fernández-Salazar L; Gutiérrez A; Van Domselaar M; López-SanRomán A; Ber Y; García-Sepulcre M; Ramos L; Bermejo F; Gisbert JP;
Inflamm Bowel Dis; 2016 Apr; 22(4):894-901. PubMed ID: 26933750
[TBL] [Abstract][Full Text] [Related]
34. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: A single-center retrospective study.
Ezzedine K; Visseaux L; Cadiot G; Brixi H; Bernard P; Reguiai Z
J Dermatol; 2019 Apr; 46(4):322-327. PubMed ID: 30816581
[TBL] [Abstract][Full Text] [Related]
35. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
[TBL] [Abstract][Full Text] [Related]
36. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
Shivaji UN; Sharratt CL; Thomas T; Smith SCL; Iacucci M; Moran GW; Ghosh S; Bhala N
Aliment Pharmacol Ther; 2019 Mar; 49(6):664-680. PubMed ID: 30735257
[TBL] [Abstract][Full Text] [Related]
37. Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study [Formula: see text].
Cossio ML; Genois A; Jantchou P; Hatami A; Deslandres C; McCuaig C
J Cutan Med Surg; 2020; 24(4):333-339. PubMed ID: 32527153
[TBL] [Abstract][Full Text] [Related]
38. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
39. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
40. Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.
Segaert S; Hermans C
Am J Clin Dermatol; 2017 Dec; 18(6):771-787. PubMed ID: 28597181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
